Portage Biotech Inc (CSE:PBT) (NASDAQ:PRTG) CEO Dr Ian Walters tells Proactive the clinical stage immuno-oncology company is looking forward to trading its shares on the Nasdaq Stock Exchange on February 25th.
Dr Walters explains how the Toronto-based group's listing on the Nasdaq made sense, as it now has 'momentum' going into clinical data readouts from its three lead assets. He expects the listing to expand the investor base and better approach specialist investors within the biotech sector.